Company Description
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States.
The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies.
It also develops Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in Phase 2 clinical trial; Quemliclustat, a small-molecule CD73 inhibitor, which is Phase 1b and Phase 2 clinical trial; Zimberelimab, an anti-PD-1 antibody, which is in Phase 2 clinical trial for metastatic cell lung cancer and monotherapy; and AB521, an oral and small-molecule inhibitor of HIF-2a, which is in Phase 1 clinical trial for the treatment of Von Hippel-Lindau disease.
In addition, the company's preclinical pipeline products include AB598, a CD39 antibody; and AB801, a small molecule Axl inhibitor.
It has a clinical collaboration with AstraZeneca to evaluate domvanalimab in combination with durvalumab in a registrational phase 3 clinical trial in patients with unresectable Stage 3 NSCLC; and BVF Partners L.P. to support the discovery and development of compounds for the treatment of inflammatory diseases.
Arcus Biosciences, Inc. was incorporated in 2015 and is headquartered in Hayward, California.
| Country | United States |
| Founded | 2015 |
| IPO Date | Mar 15, 2018 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 577 |
| CEO | Dr. Terry J. Rosen Ph.D. |
Contact Details
Address: 3928 Point Eden Way Hayward, California 94545 United States | |
| Phone | (510) 694-6200 |
| Website | arcusbio.com |
Stock Details
| Ticker Symbol | RCUS |
| Exchange | NYSE |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001724521 |
| CUSIP Number | 03969F109 |
| ISIN Number | US03969F1093 |
| Employer ID | 47-3898435 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Terry J. Rosen Ph.D. | Co-Founder, Chairman and Chief Executive Officer |
| Dr. Juan Carlos Jaen Ph.D. | Co- Founder and President |
| Robert C. Goeltz II | Principal Financial Officer and Chief Financial Officer |
| Jennifer A. Jarrett M.B.A. | Chief Operating Officer |
| Dr. Dimitry S.A. Nuyten M.D., Ph.D. | Chief Medical Officer |
| Dr. K. Christopher Garcia Ph.D. | Co-Founder and Member of Scientific Advisory Board |
| Alexander Azoy | Vice President of Finance and Principal Accounting Officer |
| Dr. Jonathan Yingling Ph.D. | Chief Scientific Officer |
| Carolyn C. Tang J.D. | General Counsel and Corporate Secretary |
| Holli Kolkey | Vice President of Corporate Communications |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 24, 2024 | ARS | Filing |
| Apr 23, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 23, 2024 | DEF 14A | Other definitive proxy statements |
| Mar 27, 2024 | 144 | Filing |
| Mar 15, 2024 | 144 | Filing |
| Feb 21, 2024 | S-3ASR | Automatic shelf registration statement of securities of well-known seasoned issuers |
| Feb 21, 2024 | S-8 | Securities to be offered to employees in employee benefit plans |
| Feb 21, 2024 | 10-K | Annual Report |
| Feb 21, 2024 | 8-K | Current Report |
| Feb 13, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |